Somagenetix AG Fuels Growth with CHF 10 Million Financing
In a major leap forward, Somagenetix AG, a leader in gene therapy development, has successfully closed a Series A financing round, raising CHF 10 million. This funding round is spearheaded by Vi Partners, a distinguished venture capital firm renowned for its investments in life sciences and technology sectors. Other notable investors that participated include Schroders Capital, Zürcher Kantonalbank, and Verve Ventures.
Advancing Gene Therapy for Chronic Granulomatous Disease
The capital raised will serve as a catalyst for advancing Somagenetix’s promising gene therapy candidate known as SGX-001. This therapy is designed specifically for treating p47 Chronic Granulomatous Disease (CGD), a serious inherited immunodeficiency that increases susceptibility to recurrent life-threatening infections. The underlying cause of CGD stems from genetic defects that hinder the functionality of phagocytes, which are essential immune cells in the body. Current treatment modalities primarily rely on stem cell transplants, a procedure dependent on the availability of a matching donor.
Expert Insights from Somagenetix Leadership
Prof. Dr. Janine Reichenbach, a co-founder of Somagenetix AG, shared insights regarding the company’s innovative approach. She emphasized, "Our team at the University of Zurich has successfully developed a best-in-class lentiviral gene therapy platform tailored for phagocyte disorders. We've validated our method through extensive preclinical studies and are eager to initiate clinical trials for SGX-001 in the near future." This statement underscores their dedication to pioneering solutions that target severe immunodeficiencies.
New Leadership with Dr. Andrin Oswald
In conjunction with the financing announcement, Somagenetix AG welcomed Dr. Andrin Oswald as its new CEO. With over twenty years of experience leading pharmaceutical ventures, Dr. Oswald has held various prominent roles across both small and large drug companies, positioning him as a vital asset for Somagenetix's future. He holds a doctorate in medicine from the University of Geneva.
Looking Ahead: A Vision for the Future of Healthcare
Dr. Oswald expressed enthusiasm about the future, stating, "Joining Somagenetix is an exciting venture for me. With this new funding, we are poised to take significant steps toward clinical development. Should our technology prove effective in CGD, we see immense potential for treating a broad spectrum of severe phagocyte-related disorders." This reflects a strong commitment to advancing patient care through innovative therapies.
What Vi Partners Sees in Somagenetix
Dr. Diego Braguglia, Managing Partner at Vi Partners, shared the firm's perspective on their investment. "Supporting Somagenetix represents a commitment to transformative personalized medicine. The innovative lentiviral technology they have developed holds promise for significant advancements that could change lives internationally. We are thrilled to be part of this groundbreaking journey towards improving global health outcomes."
About Somagenetix AG
Founded in 2019 as a spinoff from the University of Zurich, Somagenetix AG is at the cutting edge of gene therapy innovation. Its mission focuses on curing phagocyte disorders through one-time treatments. The proprietary technology developed by the company seeks to surpass limitations associated with traditional gene therapies, providing enhancements in safety and targeted cellular specificity while ensuring long-term effectiveness.
Collaboration with Wyss Zurich Translational Center
The development of SGX-001 is bolstered by the support of the Wyss Zurich Translational Center. This esteemed joint project between the University of Zurich and ETH Zurich serves as an accelerator focusing on the transition from research to viable clinical therapies. The center's mission is to advance not just treatment protocols but also innovative technologies aimed at improving patient outcomes.
About Vi Partners
Vi Partners has established itself as one of Central Europe's premier venture capital investors, contributing to the innovation landscape in healthcare and technology for over two decades. Their extensive network of entrepreneurs and thought leaders exemplifies a commitment to fostering ground-breaking advancements in early-stage companies.
Contact Information
Marius Herrmann
Head of Operations
Somagenetix AG
Email: info@somagenetix.com
Website: www.somagenetix.com
Frequently Asked Questions
What is Somagenetix AG known for?
Somagenetix AG is recognized for its pioneering work in gene therapy focused on treating phagocyte disorders.
What was the amount raised in the Series A financing?
The company raised CHF 10 million in its latest financing round led by Vi Partners.
What condition does SGX-001 target?
SGX-001 is intended for the treatment of p47 Chronic Granulomatous Disease, an inherited immunodeficiency.
Who is the new CEO of Somagenetix AG?
Dr. Andrin Oswald has been appointed as the CEO, bringing extensive pharmaceutical leadership experience.
What is the Wyss Zurich Translational Center?
It is an accelerator that fosters research initiatives aimed at developing clinical therapies and innovative technologies.
